Abstract
In Mexico, HPV vaccines available immunize against genotypes 16/18 and 16/18/6/11; however, there is limited surveillance about carcinogenic subtypes in different states of the country that allow evaluating the effectiveness of vaccination and cervical cancer screening programs. Here, we report the regional and age-specific prevalence of 14 hr-HPV genotypes as well as their prevalence in abnormal cytology (from ASCUS to cervical cancer) among Mexican women which were undergoing from cervical cancer screening in the Salud Digna clinics in 20 states of the country. This study includes women with social security from the majority of public health institutions (IMSS, ISSSTE, SEMAR, and PEMEX), and women without social security. For cervical cancer screening, we used the SurePath liquid-based cytology and the BD Onclarity HPV Assay. From December 1, 2016, to August 2, 2018, the hr-HPV prevalence among 60,135 women was 24.78%, the most prevalent types were HPV 16 (4.13%), HPV 31 (4.12%) and HPV 51 (3.39%), while HPV 18 (1.70%) was less prevalent among infected women. Interestingly, the genotypes not covered by current vaccines in Mexico were commonly found in precancerous lesions, evidencing their carcinogenic potential, so it is necessary to increase their surveillance and inclusion in cervical cancer screening triage.
Highlights
In Mexico, human papillomavirus (HPV) vaccines available immunize against genotypes 16/18 and 16/18/6/11; there is limited surveillance about carcinogenic subtypes in different states of the country that allow evaluating the effectiveness of vaccination and cervical cancer screening programs
We found that the prevalence of high risk-HPV genotypes (hr-HPV) was 21.21% in women negative for intraepithelial lesions or malignancy (NILM), 73.04% in atypical squamous cells with undetermined significance (ASCUS), 82.14% in atypical squamous cells cannot exclude high-grade squamous intraepithelial lesions (ASC-H), 73.68% in atypical glandular cells (AGC), 84.09% in low-grade squamous intraepithelial lesions (LSIL), 92.22% in high-grade squamous intraepithelial lesions (HSIL), and 78.57% in cervical cancer cases (Table 4)
We show the prevalence of carcinogenic HPV types among Mexican women undergoing cervical cancer screening in private outpatient care Salud Digna clinics
Summary
In Mexico, HPV vaccines available immunize against genotypes 16/18 and 16/18/6/11; there is limited surveillance about carcinogenic subtypes in different states of the country that allow evaluating the effectiveness of vaccination and cervical cancer screening programs. Regarding HPV prevalence, different works had been carried out in some states of the country (Supplementary Table S1); the majority analyzed women with social security.
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
